Pregnancy and postpartum outcomes in a universally tested population for SARS‐CoV‐2 in New York City: a prospective cohort study

M Prabhu,K Cagino,KC Matthews,RL Friedlander,SM Glynn,JM Kubiak,YJ Yang,Z Zhao,RN Baergen,JI DiPace,AS Razavi,DW Skupski,JR Snyder,HK Singh,RB Kalish,CM Oxford,LE Riley
DOI: https://doi.org/10.1111/1471-0528.16403
2020-08-13
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>To describe differences in outcomes between pregnant women with and without COVID‐19</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Design</h3><p>Prospective cohort study of pregnant women consecutively admitted for delivery, and universally tested via nasopharyngeal (NP) swab for SARS‐CoV‐2 using reverse transcriptase polymerase chain reaction (RT‐PCR). All infants of mothers with COVID‐19 underwent SARS‐CoV‐2 testing.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Setting</h3><p>Three New York City hospitals</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Population</h3><p>Pregnant women &gt; 20 weeks' gestation admitted for delivery</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Data were stratified by SARS‐CoV‐2 result and symptomatic status, and summarized using parametric and nonparametric tests.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Main Outcome Measures</h3><p>Prevalence and outcomes of maternal COVID‐19; obstetric outcomes; neonatal SARS‐CoV‐2; placental pathology.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Of 675 women admitted for delivery, 10.4% were positive for SARS‐CoV‐2, of whom 78.6% were asymptomatic. We observed differences in sociodemographics and comorbidities between women with symptomatic vs. asymptomatic vs. no COVID‐19. Cesarean delivery rates were 46.7% in symptomatic COVID‐19, 45.5% in asymptomatic COVID‐19, and 30.9% without COVID‐19 (p=0.044). Postpartum complications (fever, hypoxia, readmission) occurred in 12.9% of women with COVID‐19 vs 4.5% of women without COVID‐19 (p&lt;0.001). No woman required mechanical ventilation, and no maternal deaths occurred. Among 71 infants tested, none were positive for SARS‐CoV‐2. Placental pathology demonstrated increased frequency of fetal vascular malperfusion, indicative of thrombi in fetal vessels, in women with vs. without COVID‐19 (48.3% vs 11.3%, <i>p </i> &lt;0.001). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>Among pregnant women with COVID‐19 at delivery, we observed increased cesarean delivery rates and increased frequency of maternal complications in the postpartum period. Additionally, intraplacental thrombi may have maternal and fetal implications for COVID‐19 infections remote from delivery.</p></section>
What problem does this paper attempt to address?